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DOI: [10.1016/j.foodchem.2019.125601](10.1016/j.foodchem.2019.125601){#intref0010}**Value of the Data**•This data collects *in vitro, in vivo* and *ex vivo* information about amaranth protein and peptides with antihypertensive effect. The interaction of the different approaches is important for understanding the mechanism of action of amaranth peptides.•The data will help to understand the possible mechanism of action of food peptides on the RAS system.•Data are useful for researchers and academician to acquire innovative knowledge about the effect of bioactive peptides on RAS system. In addition, data provide new insights and information to consider in the design of novel functional foods with amaranth what could be useful for entrepreneurs and food industry.•How affect the bioactive peptides on RAS system is a valuable tool to develop a new functional food. Emulsions with amaranth proteins could be a delivery system of antihypertensive peptides with the possibility to enhance the biodisponibility and reach the target organ successfully.

1. Data description {#sec1}
===================

Data describes the effect of amaranth protein/peptides on RAS system inquiring into the mechanism of action of these samples using *in vitro*, *in vivo* and *ex vivo* approaches \[[@bib1]\].

Treatment groups were:1.G~W~: Negative control group. Animals treated with water, which did not receive amaranth proteins.2.G~C~: Captopril group. Animals treated with captopril, an ACE inhibitor.3.G~A~: Aliskiren group. Animals treated with aliskiren, a renin inhibitor.4.G~API~: API group. Animals treated with amaranth protein isolated (API).5.G~AH~: AH group. Animals treated with amaranth protein hydrolysate (AH).6.G~VIKP~: VIKP group. Animals treated with the synthetic peptide VIKP.7.G~E~: w/o Emulsion group. Animals treated with w/o emulsion.8.G~E+VIKP~: w/o Emulsion + VIKP group. Animals treated with w/o emulsion added with VIKP.

In order to compare mean values, a one way analysis of variance (ANOVA) multiple comparisons was applied. The critical significance level was set at p \< 0.05. All samples were compared to G~W~ (negative control group).

[Table 1](#tbl1){ref-type="table"} shows the reduction in SBP values exerted in each experimental group. Data were expressed as the decrease of SBP in mmHg of animals 3 h after the administration of each sample with respect to the SBP measured at the beginning of the experiment (SBP~3h~-SBP~0hi~). ΔP values are presented as mean ± SEM. Animals belonging to the G~E~ and G~E+VIKP~ groups showed the most significant reduction in the SBP reaching reduction values of 42 ± 2 mmHg and 35 ± 2 mmHg respectively. The administration of API, AH or VIKP in water as vehicle (G~API~, G~AH~ y G~VIKP~ groups) caused a reduction in SBP values that was significantly lower than those observed in the groups mentioned above (25 ± 14 mmHg, 26 ± 3 mmHg and 21 ± 3 mmHg respectively.)Table 1Systolic blood pressure before and after treatment. ΔP (SBP~3h~-SBP~0hi~) values are presented as mean ± SEM.Table 1Treatment groupSBP (mm Hg)1234567891011121314G~W~196281215190188206176280193195177196200273244202170201average191278217196178201post intragastric administration201314208228167188186283179222152187196244156203162250average194280181218160208ΔP = SBP3~h~-SBP~0hi~42−3622−187**ΔP average-3**^**a**^**SEM8**G~A~196185195196197183187192190186185193average194185189194post intragastric administration145156139139147154140135152150145140average148153141138ΔP = SBP3~h~-SBP~0h~−46−31−48−56**ΔP average−45**^**b**^**SEM5**G~C~208205--205199205--193199205--183average202205194post intragastric administration166171--168159173--171162177--163average162174167ΔP = SBP3~h~-SBP~0h~−40−31−26**ΔP average−32**^**b**^**SEM4**G~API~166162197180259160166208187238159168204190234average162165203186244post intragastric administration153155136140179145157147154173158154152162182average152155145152178ΔP = SBP3~h~-SBP~0h~−10−10−58−34−66**ΔP average−35**^**b**^**SEM12**G~AH~181184184162159174203199208183162168170195184184186159161179192184198173166182181191average182177188158164177191173199169160177182185182182186160161177195185202175163176178190post intragastric administration145166165145140156167--176146123148150146156159166156145158161--177148116141158148156168158151146155168--177146129145157139average152164163151144156165--177147123145155144ΔP = SBP3~h~-SBP~0h~−30−17−23−9−18−20−30--−25−28−40−31−23−46**ΔP average−26**^**b**^**SEM3**G~VIKP~209223223221205208201201206222201218208209199203205219208219208205203206average207221211219207207201203post intragastric administration188193183188200193182179191192181190201183181177195199177195205188180185average191195180191202188181180ΔP = SBP3~h~-SBP~0h~−15−27−30−28−5−19−20−23**ΔP average−21**^**b**^**SEM3**G~E~188181187183181178190192186183182187179180196198191187202185179177191196average188184190185180178192195post intragastric administration151140142145144142157148145143142147142141146145142145149142148145145141average146143144145145143149145ΔP = SBP3~h~-SBP~0h~−42−41−46−40−35−36−43−51**ΔP average−42**^**b**^**SEM2**G~E+VIKP~173155153151171169171175169177174175177175169171175173173174173average172165168166173173173post intragastric administration132138132138132137135135136135137134132134137134136135137135136average135136134137134135135ΔP = SBP3~h~-SBP~0h~−38−29−34−29−39−39−38**ΔP average−35**^**b**^**SEM2**

[Table 2](#tbl2){ref-type="table"} shows ACE plasma concentration of different groups assayed. This ELISA immunoassay is based on a competitive inhibition. Calibration curve was calculated according to the manufacturer\'s directions and the values are as follows: y = 0.7089 e ^(−0.001405.X)^ + 0.107 where "y" means OD at 450nm and "x" is ACE sample concentration in μg/ml. It can be observed that G~W~ group presented extremely low values of ACE levels (0.17 ± 0.02 μg/ml), whereas ACE concentration in G~C~ G~A~ G~E~ y G~E+VIKP~ groups were 13.6--25.8 times higher than control group. API, AH and VIKP (G~API~,G~AH~,G~VIKP~ groups respectively) induced an increase in the ACE levels that was 7.6 to 5.3 times higher than control group (1.3 ± 0.2 μg/ml, 0.90 ± 0.3 μg/ml and 1.1 ± 0.3 μg/ml respectively. p \< 0.05). The same trend has been observed in studies evaluating synthetic drugs in hypertension treatments \[[@bib4],[@bib5]\].Table 2Plasma ACE concentration at the end of the 3 h treatment. Values are presented as mean ± SEM.Table 2Treatment groupRatOD~450~ (nm)μg/mlAverageSDSEMG~W~10.5920.140.15^a^0.070.0320.5790.1430.7610.0340.4640.2450.5360.18G~A~10.1810.802.08^b^0.840.4220.0812.5030.0772.5040.0762.50G~C~10.0892.502.50^b^0020.0782.5030.092.50G~API~10.1341.161.35^b^0.520.320.111.9430.1560.95G~HA~10.1840.791.16^b^0.880.3920.1161.5530.0952.5040.4380.2750.2150.67G~VIKP~10.1510.990.87^b^0.640.3220.2270.6330.5390.1840.1131.70G~E~10.0562.502.50^b^0020.0572.5030.0572.5040.0562.5050.0622.5060.0572.5070.0582.50G~E+VIKP~10.0622.502.29^b^0.460.220.0552.5030.1191.4540.062.5050.0572.50

[Table 3](#tbl3){ref-type="table"} shows renin plasma concentration in the different samples assayed. Calibration curve obtained was y = 0.005x + 0.008 where "y" means OD at 450 nm and "x" represented renin concentration in pg/ml. Only the G~A~, G~API~ and G~AH~ groups presented differences in plasma renin levels, as compared to G~W~ group. No differences were found in the levels of this enzyme between G~C~, G~E~, G~VIKP~ and G~E+VIKP~ groups and the control group G~W~.Table 3Plasma renin concentration at the end of the 3 h treatment. Values are presented as mean ± SEM.Table 3Treatment groupRatOD~450~ (nm)pg/mlAverageSDSEMG~W~10.2790.30554.259.442.4^a^9.93.120.1830.1713532.630.2520.22148.842.640.2230.2394346.250.1580.1713032.6G~A~10.1990.17538.233.434.2^b^4.71.920.2160.1641.630.430.1660.15831.630G~C~10.1930.178373435.1^a^3.41.420.1760.15933.630.230.210.18540.435.4G~API~10.130.15124.428.634.0^b^7.32.520.2280.2224442.830.1370.17725.833.840.1930.1843735.2G~AH~10.1570.15529.829.430.7^b^4.11.920.1930.1523728.830.1410.14326.62740.1940.15737.229.8G~VIKP~10.1920.1536.828.434.9^a^4.71.920.2210.1742.632.430.180.18134.434.6G~E~10.2070.16739.831.835.1^a^4.71.920.1630.1593130.230.2120.19240.836.8G~E+VIKP~10.2370.20945.840.236.3^a^9.6320.1920.17536.833.430.2360.22745.643.840.1240.11523.221.4

[Table 4](#tbl4){ref-type="table"} shows % ACE activity/μg ACE in plasma collected after treatments. Data are expressed as relative to 100% ACE activity to water control group (G~W~). The lowest activity values (4--7% active ACE/μg ACE) corresponded to groups G~C~, G~A~, G~E~ and G~E+VIKP~, whereas the highest activity values were found in G~VIKP~, G~AH~ and G~API~ groups, which presented 20--13% active ACE/μg ACE. The administration of different samples decreases the enzymatic activity of ACE, together with an increase in plasma levels ([Table 2](#tbl2){ref-type="table"}), probably to counter balance the inhibitory effect exerted by the hypotensive peptides.Table 4Plasma ACE activity. These data are expressed as relative to 100% ACE activity to water control group (Cw). Data are presented as mean ± SEM.Table 4Treatment groupRatsDO~382~(nm)μg enzymeDO~382~/μg enzymeActivity (%)/μg enzymeAverageSDSEMG~W~10.7940.7730.0037214.6208.8104.5101.7100.0^a^4.80.0120.7900.7250.0037213.4196.0103.995.530.6890.7520.0037186.3203.390.799.040.7850.7980.0037212.2215.8103.4105.150.7680.7210.0037207.7195.0101.295.0G~A~10.8450.7710.051916.314.97.87.17.3^b^0.20.0120.7860.7810.051915.115.07.37.230.7910.7810.051915.215.07.37.240.7710.8010.051914.915.47.17.4G~C~10.7330.7900.062511.712.65.66.15.8^b^0.20.0120.7640.7850.062512.212.65.96.030.7100.7560.062511.412.15.55.8G~API~10.723--0.033821.4--10.310.7^b^0.30.0120.761--0.033822.5--10.830.7570.7850.033822.423.210.811.240.7480.7390.033822.121.910.610.5G~AH~10.7470.7560.021834.334.716.516.716.9^b^0.50.0120.7160.7520.021832.834.515.816.630.7910.7470.021836.334.317.516.540.8010.7760.021836.735.617.717.250.7760.7710.021835.635.417.217.0G~VIKP~10.7940.7990.021836.436.717.517.617.7^b^0.50.0120.8090.7990.021837.136.717.817.630.7440.8190.021834.137.616.418.140.8040.7990.021836.936.717.717.650.8400.8140.021838.637.318.517.960.8240.8090.021837.837.118.217.870.7990.7850.021836.736.017.617.3G~E~10.7420.7650.062511.912.25.75.95.8^b^0.1020.7850.7900.062512.612.66.06.130.7420.7560.062511.912.15.75.840.7510.7560.062512.012.15.85.850.7650.7700.062512.212.35.95.960.7420.7470.062511.912.05.75.870.7250.7750.062511.612.45.66.0G~E+VIKP~10.7850.6840.057313.711.96.65.76.4^b^0.30.0120.7700.7850.057313.413.76.56.630.7750.7610.057313.513.36.56.440.7560.7650.057313.213.46.46.450.8210.7650.057314.313.46.96.4

[Table 5](#tbl5){ref-type="table"} shows the contractile activity determined in presence of potassium ions. Contractile force was higher in G~W~, G~C~ and G~A~ groups (roughly 0.45 g/mg), whereas this activity was significantly lower in the animals belonging to groups G~API~, G~VIKP~, G~E+VIKP~, G~AH~ and G~E~ (0.34--0.29 g/mg). Upon treating aorta rings with physiological concentrations of norepinephrine, statistically differences were observed in G~VIKP~ and G~E+VIKP~ groups.Table 5Effect of different samples on isolated aortic rings contracted by exposure to a high concentration of: Potassium ion (80 mM) and Norepinephrine (10^−6^ M). F~b1~ (g): basal force before K addition. F~b2~ (g): basal force before N addition. F~c~ (g): contractile force. N: norepinephrine. K: potassium ion. AW: aorta weight. Data are presented as mean ± SEM.Table 5Treatment groupRatsF~b1~ (g)F~c~ K (g)F~b2~ (g)F~c~ N (g)AW (mg)F~c~ K (g/mg)F~c~ N (g/mg)G~w~101.150.182.062.690.4280.69920.071.280.221.792.330.5190.6743−0.080.80.141.22.240.3930.4734−0.131.080.121.253.40.3560.3325−0.031.180.021.093.210.3770.33360.021.20.141.362.580.4570.473average**0.42**^**a**^**0.50**^**a**^SD**0.060.17**SEM**0.020.07**G~A~1−0.0421.1130.0561.2533.470.3330.3452−0.071.015−0.0071.2392.000.5430.62330.0211.1130.00351.2532.420.4510.51640.0210.7420.0491.0011.950.3700.538average**0.44**^**a**^**0.49**^**a**^SD**0.110.14**SEM**0.050.07**G~C~10.031.68−0.151.293.950.4180.36520.071.540.591.853.450.4260.3653−0.051.3401.573.120.4460.503average**0.43**^**a**^**0.41**^**a**^SD**0.010.08**SEM**0.010.05**G~API~12.12.952.13.482.560.3320.53921.982.672.193.213.120.2210.32732.083.292.293.733.940.3070.36540.10.90.31.22.850.2810.316500.90.11.11.90.4740.5266010.21.32.630.3800.418average**0.332**^**b**^**0.415**^**a**^SD**0.0870.098**SEM**0.0360.040**G~AH~1−0.11.20.41.52.500.520.442−0.11.50.31.82.980.5370.503300.90.21.12.380.3780.3784−0.020.5995−0.2750.80852.060.3010.52650.060.6655−0.060.90751.900.3190.5096−0.040.8525−0.0991.0891.910.4670.62270.070.528−0.1650.7592.240.2040.41380.030.7645−0.04950.9352.200.3340.4489−0.040.72−0.1260.8942.220.3420.45910−0.010.82620.010810.4762.410.3470.430110.040.6240.0420.722.010.2910.33712−0.070.402−0.0420.5281.870.2520.305130.020.5200.0160.6683.280.1520.199average**0.340**^**b**^**0.43**^**a**^SD**0.110.11**SEM**0.030.03**G~VIKP~10.0140.8680.0491.3163.150.2710.40220.0770.8610.0771.2393.000.2610.3873−0.0980.84−0.0491.2043.300.2840.38040.0141.1620.071.612.860.4010.53850.021.27−0.150.842.750.4550.360601.05601.042.810.3760.370701.24−0.0161.13.370.3680.33180.0561.008−0.040.93.610.2640.260average**0.335**^**b**^**0.379**^**b**^SD**0.0690.073**SEM**0.030.03**G~E~10.040.979−0.08251.0942.420.3880.4862−0.020.715−0.0440.9021.610.4570.58830.04950.89101.1442.020.4170.56640.01620.6696−0.11340.87482.300.2840.43050.10.476−0.4130.8262.850.1320.43560.240.567−0.2870.6232.000.1640.45570.260.6160.0561.0082.090.1700.456average**0.287**^**b**^**0.488**^**a**^SD**0.1350.064**SEM**0.050.02**G~E+VIKP~1−0.0120.69−0.060.7682.730.2570.30320.06160.6496−0.0280.62162.440.2410.2663−0.030.78−0.1150.8552.790.2900.34840.0280.8008−0.0560.99682.600.2970.40550.021.2−0.110.752.700.4370.3196−0.011.05−0.110.6423.130.3390.2407−0.081.1−0.170.6023.010.3920.256average**0.322**^**b**^**0.305**^**b**^SD**0.0720.058**SEM**0.030.02**

2. Experimental design. Materials and methods {#sec2}
=============================================

2.1. Samples {#sec2.1}
------------

The following samples were used for *in vivo* assays:-Amaranth protein isolate (API) and hydrolysate (AH) prepared from *Amaranthus hypochondriacus* as described elsewhere \[[@bib2]\]. The protein content was 87 ± 1 and 57 ± 2% w/w w.b. for API and AH respectively.-VIKP peptide, which is a synthetic peptide from 11S amaranth protein. This peptide has inhibitory activity on ACE \[[@bib6]\].-O/W 20:80 emulsions prepared with sunflower oil and 1:1 protein mixture of API and AH at pH 2 with a total protein concentration of 2% w/v with or without VIKP peptide \[(API50 + AH50)-2%+VIKP and (API50 + AH50)-2%, respectively\].

Emulsions were prepared according to \[[@bib2]\]. Emulsions were frozen at −80 °C, lyophilized and resuspended as required. Before administration, the resuspended emulsions were homogenized with a magnetic stirring bar.

\- Commercial ACE and renin inhibitors (captopril and aliskiren, respectively) were employed as positive controls.

2.2. *In vivo* assays {#sec2.2}
---------------------

### 2.2.1. Indirect measurement of blood pressure {#sec2.2.1}

The systolic blood pressure was measured according to \[[@bib3]\]. In order to determine baseline values, blood pressure values were recorded at least three times on different days for each rat. After recording the last baseline blood pressure value, an aqueous suspension of each sample was administered to each animal. Three hours after the administration, blood pressure values were recorded with a tail cuff and a pulse sensor (NarcoBiosystems, Houston, TX).

### 2.2.2. Determination of plasma ACE and renin concentrations {#sec2.2.2}

A commercial ELISA kit (Rat Angiotensin converting enzyme MBS703086, MyBioSource, CA, USA) was employed to determine ACE concentration according to manufacturer\'s directions. This immunoassay is based on a competitive inhibition. Briefly, microtitre plates are coated with ACE. Samples and standards are incubated together with an anti-ACE HRP-labeled conjugate to generate the competition. Plasma renin concentration was determined with a commercial ELISA kit (Rat renin ELISA kit MBS041519 MyBioSource) following the manufacturer\'s directions. This immunoassay is a direct ELISA, which has an analytical measurement range of 6.25--200 pg/ml. The final colour reaction was read in a microtiter plate reader (Biotek Synergy HT, Winooski, VT, USA) at 450 nm.

### 2.2.3. Determination of plasma ACE activities {#sec2.2.3}

ACE-inhibitory activity was assayed according to \[[@bib2]\]. Briefly, to determine the enzymatic activity, 50 μl of buffer \[0.2M sodium borate pH 8.3; 2M NaCl), 25 μl of milli Q water, 25 μl of the commercial enzyme (maximum activity control)\], or plasma samples were incubated with 100 μl of synthetic substrate (HHL) at 37 °C for 30 min. The reaction was stopped by heating the mixture over a water bath at 90 °C for 15 min. After cooling, 600 μl of 0.2M potassium pH 8.2 and 515 μl of colour reagent, which reacts with the hippuric acid generated during the enzymatic reaction, were added and stirred vigorously with a vortex and then centrifuged for 10 min at 20 °C and 3000×*g*. The absorbance was measured at 382 nm in a spectrophotometer (Beckman DU 650). The reaction blank was obtained by incubating the synthetic substrate with neither the plasma samples nor the enzyme, completing the reaction volume with milli Q water. Reaction blanks without the substrate (HHL was replaced by 100 μl of borate buffer) and containing plasma samples were also included. Controls containing plasma samples and captopril were also assayed.

### 2.2.4. *Ex vivo* experiments {#sec2.2.4}

During the surgical procedure employed to obtain blood samples, the thoracic aorta was resected and placed in saline solution bubbled with 5% CO~2~ and 95% O~2~. The adjacent connective tissue was carefully removed avoiding distention of the vessel and damage to the endothelium. The aorta was then cut into 2 mm long rings. Assay was performed according to \[[@bib3]\]. The rings were gently suspended between two stainless steel wires in a water-jacketed organ baths kept at 37 °C and filled with saline solution, bubbled with a mixture of 5% CO~2~ and 95% O~2~, giving a pH of 7.40. The lower wire was fixed to a vertical plastic rod immersed in the organ bath, while the upper one was rigidly connected to a force transducer (Grass FT.03D, Grass Telefactor, West Warwick, CT, USA). Preparations were then stretched to obtain a passive force of 2 g and stabilized during 1 h, changing the solution in the chamber every 20 min. Tissue rings were then exposed to a solution containing 80mM potassium or norepinephrine 10^−6^ M. For each condition, the contractile response was recorded. At the end of the experiment, tissue rings were dried on filter paper and weighed on a precision scale. The contraction intensity was calculated as the quotient between strength and the weight of the ring (mgF/mg).
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